Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

Abstract Background The efficacy and safety of lapatinib plus capecitabine (LC or LX) versus trastuzumab plus chemotherapy in patients with HER-positive metastatic breast cancer who are resistant to trastuzumab is unknown. Methods We retrospectively analyzed data from breast cancer patients who bega...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Fan Yang, Xiang Huang, Chunxiao Sun, Jianbin Li, Biyun Wang, Min Yan, Feng Jin, Haibo Wang, Jin Zhang, Peifen Fu, Tianyu Zeng, Jian Wang, Wei Li, Yongfei Li, Mengzhu Yang, Jun Li, Hao Wu, Ziyi Fu, Yongmei Yin, Zefei Jiang
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BMC 2020-03-01
श्रृंखला:BMC Cancer
विषय:
Lapatinib
Trastuzumab
Resistance
Breast cancer
ऑनलाइन पहुंच:http://link.springer.com/article/10.1186/s12885-020-6639-4
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन